IMRX

Immuneering Corp

IMRX, USA

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

https://immuneering.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$16.8333

Analyst Picks

Strong Buy

2

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.08

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-6.56 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-6.21 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.06

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 13.43% of the total shares of Immuneering Corp

1.

Vanguard Group Inc

(2.4782%)

since

2025/06/30

2.

Vanguard Total Stock Mkt Idx Inv

(1.6582%)

since

2025/07/31

3.

Marshall Wace Asset Management Ltd

(1.3456%)

since

2025/06/30

4.

BlackRock Inc

(0.9913%)

since

2025/06/30

5.

Fidelity Select Biotechnology

(0.8999%)

since

2025/07/31

6.

Vanguard Institutional Extnd Mkt Idx Tr

(0.631%)

since

2025/07/31

7.

SOUTHPORT MANAGEMENT, L.L.C.

(0.5745%)

since

2025/06/30

8.

Geode Capital Management, LLC

(0.5399%)

since

2025/06/30

9.

FMR Inc

(0.5182%)

since

2025/06/30

10.

Morgan Stanley - Brokerage Accounts

(0.4715%)

since

2025/06/30

11.

HighTower Advisors, LLC

(0.3188%)

since

2025/06/30

12.

Fidelity Extended Market Index

(0.3184%)

since

2025/07/31

13.

State Street Corp

(0.2282%)

since

2025/06/30

14.

Bridgeway Capital Management, LLC

(0.2238%)

since

2025/06/30

15.

Extended Equity Market Fund K

(0.1806%)

since

2025/06/30

16.

TD Health Sciences - I

(0.1769%)

since

2024/12/31

17.

CI Private Wealth LLC

(0.1495%)

since

2025/06/30

18.

iShares Micro-Cap ETF

(0.1489%)

since

2025/08/31

19.

Millennium Management LLC

(0.146%)

since

2025/06/30

20.

Bridgeway Ultra-Small Company Market

(0.1169%)

since

2025/06/30

21.

Fidelity Total Market Index

(0.111%)

since

2025/07/31

22.

Tidemark LLC

(0.1041%)

since

2025/06/30

23.

Fidelity Series Total Market Index

(0.0994%)

since

2025/07/31

24.

Northern Trust Corp

(0.0932%)

since

2025/06/30

25.

JHFunds2 Health Sciences NAV

(0.0795%)

since

2025/01/31

26.

First Manhattan Co. LLC

(0.0758%)

since

2025/06/30

27.

Flower City Capital

(0.0751%)

since

2025/06/30

28.

Spartan Extended Market Index Pool F

(0.0726%)

since

2025/07/31

29.

Cubist Systematic Strategies, LLC

(0.0689%)

since

2025/06/30

30.

Bank of America Corp

(0.0668%)

since

2025/06/30

31.

XTX Topco Ltd

(0.0629%)

since

2025/06/30

32.

Avantis US Small Cap Equity ETF

(0.0547%)

since

2025/08/30

33.

Alethea Capital Management, LLC

(0.0538%)

since

2025/06/30

34.

Vanguard Balanced Index Inv

(0.0473%)

since

2025/07/31

35.

NT Ext Equity Mkt Idx Fd - L

(0.0445%)

since

2025/06/30

36.

Northern Trust Extended Eq Market Idx

(0.0445%)

since

2025/06/30

37.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0414%)

since

2024/12/31

38.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0414%)

since

2025/07/31

39.

NT Ext Equity Mkt Idx Fd - NL

(0.0396%)

since

2025/06/30

40.

Spartan Total Market Index Pool G

(0.0394%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.376

Latest Release

Date

2025-09-30

EPS Actual

-0.38

EPS Estimate

-0.41

EPS Difference

0.03

Surprise Percent

7.3171%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.